Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Transrectal intraprostatic botulinum toxin A injection for lower urinary tract symptoms due to benign prostatic hyperplasia
NL-OMON20354Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2007
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of botulinum toxin type A in benign prostatic hyperplasia (BPH), sponsored by University Medical Center Utrecht. Primary endpoint: Symptom relief according to International Prostate Symptom Score. Planned start Jan 2007; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NL-OMON20354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20354.